Applied Genetic Technologies Corp. (NASDAQ:AGTC)’s share price fell 2.8% during trading on Monday . The stock traded as low as $15.10 and last traded at $15.20, with a volume of 53,165 shares changing hands. The stock had previously closed at $15.63.

Several brokerages have commented on AGTC. Roth Capital reissued a “buy” rating on shares of Applied Genetic Technologies Corp. in a research report on Monday, April 25th. Zacks Investment Research lowered Applied Genetic Technologies Corp. from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 12th. BMO Capital Markets began coverage on Applied Genetic Technologies Corp. in a research report on Monday, April 11th. They set an “outperform” rating and a $25.00 price objective for the company. Cantor Fitzgerald reissued a “buy” rating and set a $32.00 price objective on shares of Applied Genetic Technologies Corp. in a research report on Wednesday, June 22nd. Finally, Wedbush reissued an “outperform” rating and set a $36.00 price objective on shares of Applied Genetic Technologies Corp. in a research report on Tuesday, May 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $26.00.

The firm’s 50-day moving average is $15.05 and its 200 day moving average is $15.07. The company’s market capitalization is $274.10 million.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last announced its quarterly earnings data on Monday, May 9th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.06. The firm earned $12 million during the quarter, compared to analyst estimates of $12.98 million. During the same period in the prior year, the company posted ($0.38) earnings per share. The firm’s revenue for the quarter was up 4125.4% on a year-over-year basis. Analysts anticipate that Applied Genetic Technologies Corp. will post ($0.16) EPS for the current fiscal year.

Other hedge funds recently bought and sold shares of the company. Jennison Associates LLC raised its stake in Applied Genetic Technologies Corp. by 0.5% in the fourth quarter. Jennison Associates LLC now owns 677,610 shares of the company’s stock valued at $13,823,000 after buying an additional 3,248 shares during the period. Globeflex Capital L P bought a new stake in Applied Genetic Technologies Corp. during the fourth quarter valued at approximately $1,189,000. Finally, Russell Frank Co bought a new stake in Applied Genetic Technologies Corp. during the fourth quarter valued at approximately $1,541,000.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.